This Is MS Multiple Sclerosis Community: Knowledge & Support

Just saw this interesting bit of news re: a study they did on the effectiveness of taking Interferon Beta 1b after the initial MS attack as opposed to waiting.

The drug companies, of course, tell everyone that they should start using these drugs immediately. The Mayo Clinic, a couple of years ago, suggested a wait and see course before starting treatment and they were ridiculed by some for publishing their report.

_______________________________


Research News


Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

In relapsing-remitting MS, people can experience a period which can last for several years, characterised by the presence of acute relapses. Following this, a period of slow progression of disability may appear. Interferon (IFN) beta is one of the accepted drugs for MS, as it has been proven to reduce the relapse rate in people with MS and delay the appearance of a second relapse, when given after a first attack suggestive of MS. The authors aimed to investigate whether treatment with IFN beta, when administered after a first relapse, could also delay the progression of disability in people with MS. The authors followed two groups of people with MS for five years. One of these groups started IFN beta immediately after the first relapse and the other started the treatment after the second clinical relapse. They found that the risk for confirmed progression of disability was not lower in people who had started the treatment after the first relapse than in people who had started this treatment later, suggesting that IFN beta does not seem to delay the appearance of long-term disability.

authors: Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; for the BENEFIT Study Group
source: Lancet Neurol. 2009 Sep 10
_________________________________

I leave it to draw your own conclusions.

Harry

Thanks harry. You are right. They have said for years that we should start the interferons' as quickly as possible for better outcomes down the road. Very interesting study.